参考文献/References:
[1]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941－1960. [2]陈川英,涂相林,程全红,等.慢性乙型肝炎患者妊娠早期替比夫定抗病毒的疗效及母婴阻断的临床观察[J].中华肝脏病杂志,2015,23(1):9-12. [3]European Association for the Study of the Liver.Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398. [4]李忠斌,邵清,夏晶,等.阿德福韦酯治疗失败的慢性乙型肝炎两种挽救治疗方案比较[J].武警医学,2016,27(3):253-256. [5]Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection[M].Geneva:World Health Organization,2015. [6]陈玉兰,刘洁,陈立宇.三种核苷类似物对慢性乙型肝炎患者肾 功能影响的长期随访研究[J].解放军医药杂志,2016,28(6):83-86. [7]徐勇,冯继红,李荣宽,等.不同核苷(酸)类似物治疗慢性乙型肝炎患者对eGFR的影响[J].实用肝脏病杂志,2018,12(1):50-53. [8]李华珊,马红.肾功能损伤标志物及其在核苷(酸)类似物治疗中肾功能监测的应用[J].中华肝脏病杂志,2016,24(3):234-236. [9]谷雷雷,张欣欣.乙型肝炎肝硬化患者的抗病毒治疗[J].上海交通大学学报(医学版),2015(11):1717-1721. [10]吴志勤,辛海光,杭小锋,等.核苷(酸)类似物对慢性HBV感染肝移植术后患者估算肾小球滤过率的影响[J].第二军医大学学报,2017,12(5):595-601. [11]王传敏,李新宇,陈悦.核苷(酸)类似物治疗慢性乙型肝炎达到停药标准后复发患者的临床特征和影响因素[J].河北医学,2015,21(1):140-143. [12]姚光弼,王宝恩,崔振宇.拉米夫定治疗慢性乙型肝炎三年疗效观察[J].中华内科杂志,2003,42(6):382-387. [13]朱冬梅,叶春艳,钱梅云,等.替诺福韦酯挽救治疗耐药复发的慢性乙型肝炎患者48周疗效初探[J].实用肝脏病杂志,2016(1):37-40. [14]毛海鹰,廖礼艳,胡秋菊,等.恩替卡韦治疗慢加急性乙型肝炎肝衰竭疗效分析[J].实用肝脏病杂志,2015(5):491-495 [15]李春进,吴双,张李雅,等.恩替卡韦治疗 HBeAg阳性慢性乙型肝炎的临床疗效分析[J].系统医学,2017,2(3):33-35. [16]Yuan G,Hu C,Zhou Y,et al.A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study[J].Br J Clin Pharmacol,2017,83(10):2259-2265. [17]侯金林,魏来.慢性乙型肝炎防治指南(2015更新版)[J].中国肝脏病杂志(电子版),2015, 20(12):5-22. [18]Ning Q,Han M,Sun Y,et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomisedopen-label trial (OSST trial)[J].J Hepatol,2014,61(4):777-784. [19]Wong GL,Wong VW,Chan HL.Combination therapy of interferonand nucleotide /nucleoside analogues for chronic hepatitis B[J].JViral Hepat,2014,21(12):825-834. [20]陈立,李孝楼,甘巧蓉,等.核苷(酸)类似物治疗慢性乙型肝炎停药复发患者的临床特点及其影响因素[J].中华肝脏病杂志,2015,21(11):825-828. [21]Brouwer WP,Xie Q,Sonneveld MJ,et al.Adding pegylated interferonto entecavir for hepatitis B antigen-positive chronic hepatitis B:A multicenter randomized trial (ARES study)[J].Hepatology,2015,61(5):1512-1522. [22]高峰,李建红,荀健,等.替诺福韦酯和阿德福韦酯治疗乙型肝炎e抗原阳性慢性乙型肝炎的疗效比较[J].中国药物与临床,2016,16(4):554-556. [23]张林武.阿德福韦酯联合复方甘草酸苷治疗慢性乙型肝炎的临床疗效观察[J].临床合理用药杂志,2016,9(20):45-46. [24]李国涛,臧珂.恩替卡韦与替诺福韦酯初始治疗慢性乙型肝炎的疗效比较[J].中国基层医药,2016,23(24):3790-3793. [25]Singal AK,Fontana RJ.Meta-analysis:Oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis[J].Alimentary Pharmacology&Therapeutics,2012,35(6):674-689. [26]Fung S,Kwan P,Fabri M,et al.Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B[J].Gastroenterology,2014,146(4):980-988.